Searchable abstracts of presentations at key conferences in endocrinology

ea0094op5.1 | Adrenal and Cardiovascular | SFEBES2023

Nocturnal metyrapone administration for cortisol suppression in macs: tolerability and impact on metabolic outcomes

Berry Simon , Iqbal Ahmed , Newell-Price John , Debono Miguel

Background: Mild autonomous cortisol secretion (MACS) in patients with adrenal incidentalomas has been associated with elevated cortisol levels during the nocturnal period resulting in a disturbed cortisol rhythm. We hypothesised that administration of nocturnal metyrapone, an 11-beta-hydroxylase inhibitor, previously shown to restore cortisol rhythm in MACS patients, could reduce metabolic complications in this patient group.Met...

ea0029p185 | Bone & Osteoporosis | ICEECE2012

Cimetidine (histamine H2-receptor antagonist and antiandrogenic drug) exerts a beneficial effect in the injured tissues by periodontal disease in male rat molars

Longhini R. , de Oliveira P. , Sasso-Cerri E. , Cerri P.

Studies have demonstrated the presence of androgen receptors in osteoblasts and osteocytes, confirming that androgens are important for the maintenance of bone in men. Additionally to steroid hormones, histamine stimulates osteoclast differentiation and survival and plays a role in the inflammatory response via H2 receptors. We purposed to investigate whether cimetidine, an histamine H2 receptors antagonist and antiandrogenic drug, interferes in the periodontal tissue damages ...

ea0029p1437 | Pituitary Clinical | ICEECE2012

Efficacy of transsphenoidal surgery for Cushing’s disease: the role of combined dexamethasone desmopressin test

Witek P. , Glinicki P. , Szamotulska K. , Zielinski G.

Introduction: The treatment of choice in Cushing’s disease (CD) is transsphenoidal surgery (TSS). The success of surgical procedure is of particular importance in terms of patient`s prognosis. The aim of this study was the prospective evaluation of compatibility of coupled 1 mg dexamethasone suppression test and 10 μg desmopressin stimulation test (CDDT) with standard criteria of remission in CD.Methods: The study population consisted of 36 pat...

ea0026p684 | Diabetes therapy | ECE2011

Impact of structured testing on level of glycemic control

Popovic-Pejicic S P P , Karlovic V K

Introduction: Clinical trials have show n that improved glycemic control reduces the incidence and progression of diabetes complications. One of the most important steps in diabetes treatment is to educate patients how to manage self monitorining blood glucose (SBGM) and adjust their life habits with their diabetes. A new diabetes management concept of structured testing is supported by Accu -Chek 360 View.Objectives: Assess the impact of structured test...

ea0003p248 | Steroids | BES2002

The relationship between smoking, statin therapy and testosterone in men with coronary artery disease

Morris P , Pugh P , Hall J , Channer K , Jones T

BACKGROUND: We have previously shown that men with coronary artery disease (CAD) have lower serum bioavailable testosterone levels than men with normal coronary arteries and this may have detrimental effects in coronary disease. It has been suggested that low androgen levels in men with CAD could be accounted for by the high prevalence of statin therapy and other factors such as smoking. We investigated the effects of statin therapy and smoking on testosterone in men with CAD....

ea0005p133 | Endocrine Tumours and Neoplasia | BES2003

Insulin-like growth factor binding protein-3 (IGFBP-3) expression in the caecum and rectum of patients with and without acromegaly

Khalaf S , Kelly P , Ogunkolade B , Fairclough P , Bustin S , Jenkins P

Background: Sporadic colorectal carcinoma (CRC) is more common on the left side of the colon. Acromegaly confers an increased risk of developing CRC but with an increase of right sided disease. IGFBP-3 both regulates tissue exposure to IGF-I and also exerts cellular IGF-l independent pro-apoptotic effects. Whether variation in regional IGFBP-3 expression in the colon may explain the observed pattern of disease in both normal and acromegalic patients is unknown.Aim: 1) To c...

ea0062p09 | Poster Presentations | EU2019

Chronic diarrhoea - a rare endocrine cause

Pillai Sanesh , Munir Alia , Lorenz Eleanor , Wadsley John

Case history: A 59-year-old male presented to gastroenterology with a two years of high volume persistent watery diarrhoea. He gave a past medical history of poorly controlled, insulin treated diabetes mellitus present for 8 years. He reported abdominal pain and diarrhoea that persisted despite fasting. A colonoscopy with biopsy were reported as normal. Diarrhoea, malaise, fatigue and weight loss persisted.Investigations: Stool culture and faecal elastas...

ea0037gp.28.06 | Endocrine tumours and neoplasia – NETS | ECE2015

Patient-reported time to diagnosis of neuroendocrine tumors (NETs) in Europe: results from the first global NET patient survey: a collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis

Pavel Marianne , Kolarova Teodora , Goldstein Grace , Leyden John , Sissons Maia

Background: Neuroendocrine tumor (NET) symptoms are often similar to common conditions or may not arise until metastasis occurs, delaying diagnosis and impacting survival. We present data on time to diagnosis from the European (EU) NET patient perspective.Methods: In 2014, 1928 NET patients from >12 countries (Europe (n=763): Belgium, Bulgaria, France, Germany, Norway, UK, and other EU countries (not specified); Americas; Asia; Oceania) part...

ea0037ep1139 | Endocrine tumours | ECE2015

Neuroendocrine tumor European patient experience: results from the first global NET patient survey – a collaboration between the International Neuroendocrine Cancer Alliance and Novartis

Oberg Kjell , Leyden John , Goldstein Grace , Sissons Maia , Kolarova Teodora

Background: NETs are a rare heterogeneous group of malignancies, often with a delayed diagnosis. Although diagnosis of NETs is increasing (due in part to greater awareness), little has been published on the NET patient experience. We present data on the EU NET patient perspective.Methods: In 2014, 1928 NET patients from >12 countries, including EU (n=763: Belgium, Bulgaria, France, Germany, Norway, UK, other EU countries (not specified by re...

ea0029p816 | Endocrine tumours and neoplasia | ICEECE2012

Anti-proliferative effect of GHRH antagonist JMR-132 on ovarian cancer cell via EGFR-Akt pathway

Guo J. , Schally A. , Leung P.

Antagonists of growth hormone-releasing hormone (GHRH) are being developed for the treatment of various human cancers. In this study, we investigated the effectiveness of GHRH antagonist JMR-132 treatment in ovarian cancer cell lines (SKOV-3, CaOV-3 and OVCAR-3). Using MTT assay, we found that JMR-132 has a strong anti-proliferation effects on SKOV-3 and CaOV-3 cells in a time (0, 24 h, 48 h, 72 h, 96 h) and dose (0, 25 nM, 50 nM, 100 nM and 200 nM) dependent manner. Also, JMR...